Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| OncoMed Pharmaceuticals IncOMED · Entity 158190 | Director | June 01, 2017 | June 02, 2017 |
| Revolution Medicines, Inc.RVMD · Entity 606 | Director | February 12, 2020 | February 14, 2020 |
| eFFECTOR Therapeutics, Inc.EFTR · Entity 89916 | Director | October 06, 2021 | October 08, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
OncoMed Pharmaceuticals Inc
Report date June 01, 2017 · Filed June 02, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.30 · Expires 2027-06-01 | Direct | 15,000 |
Reported balance
After 2017-06-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-01 · Grant · Acquired 15,000 · Balance 15,000 F1: The option vests as to 100% of the shares subject thereto upon the earlier of one year following the grant date or the date of the subsequent year's annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 100% of the shares subject thereto upon the earlier of one year following the grant date or the date of the subsequent year's annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date.
Revolution Medicines, Inc.
Report date February 12, 2020 · Filed February 14, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2030-02-11 | Direct | 36,168 |
Reported balance
After 2020-02-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-02-12 · Grant · Acquired 36,168 · Balance 36,168 F1: The option becomes exercisable as it vests and the shares subject to the option vest with respect to 1/36 of the shares subject thereto on each monthly anniversary of February 12, 2020, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option becomes exercisable as it vests and the shares subject to the option vest with respect to 1/36 of the shares subject thereto on each monthly anniversary of February 12, 2020, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
eFFECTOR Therapeutics, Inc.
Report date October 06, 2021 · Filed October 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.36 · Expires 2031-10-05 | Direct | 40,000 |
Reported balance
After 2021-10-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-10-06 · Grant · Acquired 40,000 · Balance 40,000 F1: The shares subject to the option will vest in substantially equal monthly installments over three years, commencing on August 25, 2021, subject to the Reporting Person's continued service with the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest in substantially equal monthly installments over three years, commencing on August 25, 2021, subject to the Reporting Person's continued service with the Issuer through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2021 Filed Oct 8, 2021 17:12 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $11.36 | $0.00 |
DisclosureSEC source: 0001209191-21-060063 · doc4.xml · derivative · entry 1 Lasky Laurence · CIK 0001553357 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-10-05 F1 · derivative.exercise_date: The shares subject to the option will vest in substantially equal monthly installments over three years, commencing on August 25, 2021, subject to the Reporting Person's continued service with the Issuer through each vesting date. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 16:26 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 36,168 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001567619-20-004028 · doc1.xml · derivative · entry 1 Lasky Laurence · CIK 0001553357 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,168 Underlying: Common Stock · 36,168 shares Expires 2030-02-11 F1 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest with respect to 1/36 of the shares subject thereto on each monthly anniversary of February 12, 2020, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 17:19 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0001140361-17-023633 · doc1.xml · derivative · entry 1 Lasky Laurence · CIK 0001553357 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-01 F1 · derivative.exercise_date: The option vests as to 100% of the shares subject thereto upon the earlier of one year following the grant date or the date of the subsequent year's annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.